tripathy
●    

2006-07-21 06:06

Posting: # 180
Views: 4,993
 

 Outlier consideration and re-dosing of Subjects [Regulatives / Guidelines]

Dear Forum member,

I am a Pharmacokinetist. I am new to this forum.
I went through some of the discussion topics, I found them really useful and decided to become a member of this forum.

I would like to ask forum members regarding the Statistical outlier consideration and re-dosing of subjects in a BE study. Whether outliers and re-dosing of subjects are acceptable by US-FDA regulatory, if yes then I would be very greatful to you if you provide me the link to any such guidance or correspondance from US-FDA.

Thanks and Regards,
Tripathy
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2006-07-21 13:33

@ tripathy
Posting: # 183
Views: 4,099
 

 Outlier consideration and re-dosing of Subjects

Hello Tripathy,

and welcome to the forum!

First have a look at this thread.
Personally I don't know any US-FDA's document regarding outliers.
You may find David Dubin's post (the last one on the page) at David Bourne's list interesting.

Generally speaking the more 'outlier conditions' you can justify in the protocol, the less trouble you will experience afterwards...
Post hoc exclusion is not a good idea!

Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes
tripathy
●    

2006-07-24 05:52

@ Helmut
Posting: # 187
Views: 3,903
 

 Outlier consideration and re-dosing of Subjects

Dear HS,

Thanks for the prompt reply. I will come back to you if I have any other doubts.

Regards,
Tripathy
Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
19,880 posts in 4,214 threads, 1,364 registered users;
online 11 (0 registered, 11 guests [including 6 identified bots]).
Forum time (Europe/Vienna): 02:11 CEST

Competence, like truth, beauty and contact lenses,
is in the eye of the beholder.    Laurence J. Peter

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5